Sentence examples for mass spectrometric technologies from inspiring English sources
Mass spectrometric technologies can provide the "phenotypic fingerprint" required for the concept of Personalized Medicine.
The science of host metabolomics is growing with the development of applications such as NMR and Mass Spectrometric technologies.
Implementation of these approaches, along with continued developments in sample preparation and mass spectrometric technologies, should enhance progress in this field.
With the use of mass spectrometric technologies, tremendous gains in the qualitative measurement of peptides from individual neurons have been made.
Mass spectrometric technologies perform optimally in the low-molecular-weight range and early reports using surface-enhanced laser desorption and ionisation time-of-flight mass spectrometry (SELDI-TOF MS) have been promising (Bhattacharyya et al, 2004; Koopmann et al, 2004; Honda et al, 2005).
The low power requirements and low mass of this novel ionisation source are considered be of great value to future space missions where mass spectrometric technology will be employed.
BrainMet (Bioimaging of Metals in Brain and Metallomics) at Forschungszentrum Jülich, Germany, provides mass spectrometric technology that enables quantitative imaging of metal distributions in brain tissue slices in combination with other medical imaging techniques (such as histochemistry, immunostaining, positron emission tomography, magnetic resonance tomography, and autoradiography).
The advancements in the mass spectrometric technology, such as in instrument designs (dual pressure ion trap) and mass analyzers (orbitrap) have significantly improved the sensitivity and mass accuracy.
The versatility of mass spectrometric technology has spawned numerous different mass spectrometers, with MALDI-TOF-TOF, Q-TOF, and Orbitrap mass analysers being among the common ones currently in use for discovery proteomics.
A previous work has applied a general mass spectrometric technology for identification and quantitation of phosphorylation sites after stimulating HeLa cells with epidermal growth factor (EGF) and recorded in the Phosida database (44).
To alleviate this limitation, we recently developed a new DIA mass spectrometric technology – SWATH MS [13], which in contrast to SRM is not based on targeted MS acquisition, but on targeted data extraction.
